Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tramiprosate nutraceutical planned

This article was originally published in The Tan Sheet

Executive Summary

Neurology drug developer Neurochem is creating a separate company to market a branded nutraceutical containing tramiprosate for Alzheimer's disease, with likely launch in 2008, after abandoning development of an Rx drug using the ingredient, the Canadian firm says Nov. 8. The decision to stop development of its oral beta-amyloid fibrillogenesis inhibitor Alzhemed comes after Neurochem announced in August that data from its Phase III North American trial showed no statistically significant difference in favor of Alzhemed versus placebo. Neurochem noted while tramiprosate did not show statistical significance in the primary endpoint in its North American trial, a preliminary post-hoc analysis, which allowed adjustment for potential confounding factors, showed a dose-dependent reduction in hippocampal atrophy in patients treated with tramiprosate versus placebo. The Laval, Quebec-based firm also said it plans to move a follow-on compound, NRM-8499, into preclinical development as an Rx product...

You may also be interested in...

Neurochem Faces Obstacles To Making Supplement Out Of Drug Candidate

Neurochem's plan to market a failed Alzheimer's disease drug candidate as a dietary supplement could stumble in the United States over requirements of the Dietary Supplement Health and Education Act, regulatory experts say

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts